Stock Research

Sleepagotchi, the Solana-based health and wellness platform where 78% of users open the app within 10 minutes of waking, today announced its next chapter: the launch of its AI Sleep Coach MVP and  strategic leadership transition. The company is graduating from gamified sleep-to-earn mechanics into “The Intelligence Layer for the Wellness Economy”, an AI-powered platform… Continue reading Sleepagotchi announces AI pivot to build intelligence layer for wellness economy

European shares moved slightly higher on Tuesday after investors reacted positively to signs of easing geopolitical tensions between the United States and Iran. Markets also assessed corporate developments, including Standard Chartered’s large-scale restructuring plans tied to artificial intelligence adoption. The pan-European STOXX 600 index rose 0.2% to 611.22 points as of 0702 GMT. However, the… Continue reading European stocks rise after Trump signals progress on Iran talks

Global fund managers raised their allocation to equities by the largest amount on record in May, supported by optimism surrounding corporate earnings growth and expectations that the Federal Reserve could begin cutting interest rates, according to Bank of America’s monthly survey released on Tuesday. The survey showed that investor sentiment toward equities improved significantly even… Continue reading Equity allocations surge as investors bet on earnings and lower rates

 London-headquartered Standard Chartered plans to cut more than 7,000 jobs over the next four years as the lender increases the use of artificial intelligence while pursuing higher profitability and operational efficiency. The bank said on Tuesday it would reduce 15% of its corporate function roles by 2030. The lender’s total global workforce stands at nearly… Continue reading Standard Chartered to cut over 7,000 jobs as AI expands

Indian stocks are stuck in a correction this week as concerns about the economy remain. The blue-chip Nifty 50 Index retreated to ₹23,650 on Tuesday, down by 10% from its highest point this year. This retreat has coincided with the crashing Indian rupee and bonds. Indian stocks retreat amid US-Iran war concerns The Nifty 50… Continue reading Nifty 50 Index at risk as Indian bond yields surge, rupee crash

Billionaire Dan Loeb’s flagship hedge fund, Third Point, recalibrated its portfolio in the first quarter of 2026, leaning heavily into the AI trade by initiating a new position in the Vaneck Semiconductor ETF (SMH). Loeb simultaneously increased exposure to individual chip-equipment makers – including ASML, Lam Research, and KLA Corp. Other notable investments he made… Continue reading Dan Loeb reveals a stake in a semiconductor ETF: find out more

US stocks ended mixed on Monday as investors monitored rising oil prices, elevated Treasury yields, and escalating tensions in the Middle East, while technology stocks extended their recent pullback after a record-setting rally earlier this month. The Dow Jones Industrial Average rose 159.95 points, or 0.32%, to close at 49,686.12. Meanwhile, the S&P 500 slipped… Continue reading Dow rises while Nasdaq slides on oil surge, Treasury yields pressure tech

Shares of Seagate Technology (STX) fell sharply on Monday after comments from CEO Dave Mosley raised investor concerns that the company may struggle to keep pace with surging artificial-intelligence-related demand for data storage solutions. Seagate shares dropped roughly 7% during trading after Mosley discussed the company’s manufacturing strategy at the JPMorgan Global Technology, Media and… Continue reading Seagate stock slides 7% as AI demand sparks capacity fears

Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal late-stage clinical trial. The sharp selloff followed Regeneron’s announcement that its high-dose fianlimab and cemiplimab combination failed to significantly outperform Merck’s Keytruda in a Phase 3… Continue reading Regeneron stock drops double digits on oncology trial failure